0.05Open0.05Pre Close12 Volume3.40K Open Interest12.00Strike Price60.00Turnover379.16%IV22.75%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0464Delta0.0396Gamma309.40Leverage Ratio-0.1788Theta0.0000Rho-14.37Eff Leverage0.0006Vega
uniQure NV Stock Discussion
Benzinga· 3 mins ago
-As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submiss...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure has reached an agreement with the FDA on key elements for an Accelerated Approval pathway for AMT-130, their Huntington's disease treatment. The FDA agreed that data from ongoing Phase I/II studies compared to natural history external control can serve as the primary basis for a Biologics License Application (BLA), eliminating the need for ad...
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$
No comment yet